Ser163

Site Information
PDKQFLIsPPAsPPV SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 456022

In vivo Characterization
Methods used to characterize site in vivo:	electrophoretic mobility shift ( 30 ) , immunoprecipitation ( 15 ) , mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 12 , 13 , 14 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ) , mutation of modification site ( 15 , 30 ) , phospho-antibody ( 15 ) , western blotting ( 15 )
Disease tissue studied:	Alzheimer's disease ( 15 ) , brain cancer ( 25 ) , glioblastoma ( 25 ) , glioma ( 25 ) , breast cancer ( 8 , 9 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , cervical cancer ( 23 ) , cervical adenocarcinoma ( 23 ) , leukemia ( 13 ) , acute myelogenous leukemia ( 13 ) , lung cancer ( 9 ) , non-small cell lung cancer ( 9 ) , melanoma skin cancer ( 2 ) , Down syndrome ( 15 )
Relevant cell line - cell type - tissue:	'brain, hippocampus' [DYRK1A (human), transgenic] ( 15 ) , 'muscle, skeletal' ( 14 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 22 ) , 293E (epithelial) ( 16 ) , breast ( 1 ) , BT-20 (breast cell) ( 9 ) , BT-549 (breast cell) ( 9 ) , Calu 6 (pulmonary) ( 9 ) , COS (fibroblast) ( 30 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 10 ) , Flp-In T-Rex-293 (epithelial) ( 10 ) , H2009 (pulmonary) ( 9 ) , H2077 (pulmonary) ( 9 ) , H2887 (pulmonary) ( 9 ) , H322M (pulmonary) ( 9 ) , HCC1937 (breast cell) ( 9 ) , HCC2279 (pulmonary) ( 9 ) , HEK293T (epithelial) ( 15 ) , HeLa (cervical) ( 3 , 7 , 18 , 24 , 28 ) , HeLa S3 (cervical) ( 23 ) , HOP62 (pulmonary) ( 9 ) , HUES-9 ('stem, embryonic') ( 17 ) , Jurkat (T lymphocyte) ( 6 , 12 , 19 , 20 , 21 , 26 , 27 ) , K562 (erythroid) ( 7 ) , KG-1 (myeloid) ( 13 ) , liver ( 5 ) , LOU-NH91 (squamous) ( 9 ) , MCF-7 (breast cell) ( 9 ) , MDA-MB-231 (breast cell) ( 9 ) , MDA-MB-468 (breast cell) ( 9 ) , NCI-H1395 (pulmonary) ( 9 ) , NCI-H1648 (pulmonary) ( 9 ) , NCI-H2030 (pulmonary) ( 9 ) , NCI-H2172 (pulmonary) ( 9 ) , NCI-H322 (pulmonary) ( 9 ) , NCI-H460 (pulmonary) ( 9 ) , NCI-H520 (squamous) ( 9 ) , PC9 (pulmonary) ( 9 ) , SKBr3 (breast cell) ( 8 ) , U87MG (glial) ( 25 ) , WM239A (melanocyte) ( 2 )

Upstream Regulation
Putative in vivo kinases:	MEKK3 (human) ( 29 )
Kinases, in vitro:	GSK3B (human) ( 15 )
Treatments:	angiotensin_2 ( 29 )

Downstream Regulation
Effects of modification on RCAN1:	activity, induced ( 29 , 30 ) , protein degradation ( 30 )
Effects of modification on biological processes:	transcription, altered ( 29 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
3	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
4	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
5	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
6	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
7	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
8	Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57 22964224 Curated Info
9	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
10	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
11	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
12	Mulhern D (2012) CST Curation Set: 13761; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
13	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
14	Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876 22673903 Curated Info
15	Jung MS, et al. (2011) Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation. J Biol Chem 286, 40401-12 21965663 Curated Info
16	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
17	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
18	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
19	Possemato A (2010) CST Curation Set: 10876; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
20	Possemato A (2010) CST Curation Set: 10875; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
21	Possemato A (2010) CST Curation Set: 10300; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996 Curated Info
22	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
23	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
24	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
25	Joughin BA, et al. (2009) An integrated comparative phosphoproteomic and bioinformatic approach reveals a novel class of MPM-2 motifs upregulated in EGFRvIII-expressing glioblastoma cells. Mol Biosyst 5, 59-67 19081932 Curated Info
26	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
27	Possemato A (2007) CST Curation Set: 3480; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
28	Olsen JV, et al. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635-48 17081983 Curated Info
29	Abbasi S, et al. (2005) The essential role of MEKK3 signaling in angiotensin II-induced calcineurin/nuclear factor of activated T-cells activation. J Biol Chem 280, 36737-46 16126726 Curated Info
30	Genescà L, et al. (2003) Phosphorylation of calcipressin 1 increases its ability to inhibit calcineurin and decreases calcipressin half-life. Biochem J 374, 567-75 12809556 Curated Info